6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial

Journal of the American College of Cardiology

Volumn 65, Issue 8, 2015, Pages 777-786

  Gilard, Martine ^a   Barragan, Paul ^b   Noryani, Arif A L ^c   Noor, Hussam A ^d   Majwal, Talib ^e   Hovasse, Thomas ^f   Castellant, Philippe ^a   Schneeberger, Michel ^g   Maillard, Luc ^h   Bressolette, Erwan ⁱ   Wojcik, Jaroslaw ^j   Delarche, Nicolas ^k   Blanchard, Didier ^l   Jouve, Bernard ^m   Ormezzano, Olivier ⁿ   Paganelli, Franck ^o   Levy, Gilles ^p   Sainsous, Joël ^q   Carrie, Didier ^r   Furber, Alain ^s   Berland, Jacques ^t   Darremont, Oliver ^u   Le Breton, Hervé ^v   Lyuycx Bore, Anne ^w   Gommeaux, Antoine ^x   Cassat, Claude ^y   Kermarrec, Alain ^m   Cazaux, Pierre ^z   Druelles, Philippe ^aa   Dauphin, Raphael ^ab   Armengaud, Jean ^ac   Dupouy, Patrick ^ad   Champagnac, Didier ^ae   Ohlmann, Patrick ^af   Endresen, Knut ^ag   Benamer, Hakim ^ah   Kiss, Robert Gabor ^ai   Ungi, Imre ^aj,ak   Boschat, Jacques ^a   Morice, Marie Claude ^f   more..

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b Polyclinique les Fleurs   (France)

^c Al Qassimi Hospital   (United Arab Emirates)

^d Bahrain Defence Force Hospital Royal Medical Services   (Bahrain)

^e DUBAI HOSPITAL   (United Arab Emirates)

^f INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^g Hôpital Albert Schweitzer   (France)

^h Clinique Axium   (France)

ⁱ Nouvelles Cliniques Nantaises   (France)

^j Medical University of Lublin Katedra i Klinika Kardiologii   (Poland)

^k CENTRE HOSPITALIER DE PAU   (France)

^l Clinique Saint Gatien   (France)

^m CENTRE HOSPITALIER   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o HÔPITAL NORD   (France)

^p Clinique Du Millenaire   (France)

^q Clinique Rhone Durance   (France)

^r TOULOUSE UNIVERSITY HOSPITAL   (France)

^s ANGERS UNIVERSITY HOSPITAL   (France)

^t Clinique Saint Hilaire   (France)

^u CLINIQUE SAINT AUGUSTIN   (France)

^v RENNES UNIVERSITY HOSPITAL   (France)

^w Centre Hospitalier Compiegne   (France)

^x Polyclinique de Bois   (France)

^y LIMOGES UNIVERSITY HOSPITAL   (France)

^z Centre Hospitalier de Lorient   (France)

^aa Clinique Saint Laurent   (France)

^ab CROIX ROUSSE HOSPITAL   (France)

^ac Clinique Esquirol   (France)

^ad Hôpital Privé   (France)

^ae Clinique du Tonkin   (France)

^af UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^ag OSLO UNIVERSITY HOSPITAL   (Norway)

^ah Hopital Europeen La Roseraie   (France)

^ai MH Egrszsegugyi Kozpont   (Hungary)

^aj Honvéd Hospital   (Hungary)

^ak UNIVERSITY OF SZEGED   (Hungary)

more..

Author keywords

double antiplatelet duration; percutaneous coronary angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; PRASUGREL; TICAGRELOR; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY STENTING; DEVICE SAFETY; DOSAGE SCHEDULE COMPARISON; DRUG ELUTING CORONARY STENT; DRUG RESPONSE; DRUG THERAPY; DUAL ANTIPLATELET THERAPY; EVEROLIMUS ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT DURATION; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; DRUG ELUTING STENT; EARLY TERMINATION OF CLINICAL TRIAL; EUROPE; HEMORRHAGE; MIDDLE EAST; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; SURGERY; TIME; TREATMENT OUTCOME;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; EARLY TERMINATION OF CLINICAL TRIALS; EUROPE; FEMALE; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MIDDLE EAST; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923348829     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.11.008     Document Type: Article

References (47)

1. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. C. Stettler, S. Wandel, and S. Allemann Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948
4. S. Bangalore, S. Kumar, and M. Fusaro Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
5. B. Kalesan, T. Pilgrim, and K. Heinimann Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 977 987
6. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
7. G. De Luca, M.T. Dirksen, and C. Spaulding Drug-eluting vs. bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials Arch Intern Med 172 2012 611 621 discussion 621-2
8. G.D. Dangas, P.W. Serruys, and D.J. Kereiakes Meta-analysis of everolimus-eluting vs. paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 6 2013 914 922
9. U. Baber, R. Mehran, and S.K. Sharma Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials J Am Coll Cardiol 58 2011 1569 1577
10. G.G. Stefanini, R.A. Byrne, and P.W. Serruys Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
11. G.G. Stefanini, U. Baber, and S. Windecker Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials Lancet 382 2013 1879 1888
12. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents vs. durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
13. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
14. M. Valgimigli, G. Campo, and M. Monti Short- vs. long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
15. S. Cassese, R.A. Byrne, and T. Tada Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials Eur Heart J 33 2012 3078 3087
16. H.C. Gwon, J.Y. Hahn, and K.W. Park Six- month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Vs. Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
17. F. Feres, R.A. Costa, and A. Abizaid Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
18. B.K. Kim, M.K. Hong, and D.H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
19. E. Kedhi, G.W. Stone, and D.J. Kereiakes Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials EuroIntervention 8 2012 599 606
20. S. Silber, A.J. Kirtane, and J.A. Belardi Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation Eur Heart J 35 2014 1949 1956
21. S. Windecker, P. Kolh, and F. Alfonso 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 35 2014 2541 2619
22. C.L. Grines, R.O. Bonow, and D.E. Casey Jr. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Coll Cardiol 49 2007 734 739
23. Aspirin Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy 1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
24. G. Krasopoulos, S.J. Brister, and W.S. Beattie Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 2008 195 198
25. P.A. Gurbel, K.P. Bliden, and J. DiChiara Evaluation of dose-related effects of aspirin on platelet function. Results from the Aspirin-Induced Platelet Effect (ASPECT) study Circulation 115 2007 3156 3164
26. E.G. Bovill, M.L. Terrin, and D.C. Stump Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial Ann Intern Med 115 1991 256 265
27. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
28. P. Vranckx, D.E. Cutlip, and R. Mehran Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
29. E. Grube, B. Chevalier, and B. Smits The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions J Am Coll Cardiol Intv 4 2011 168 175
30. E.L. Kaplan, and P. Meier Non-parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
31. D.R. Cox Regression models and life-tables J R Stat Soc B 34 1972 187 202
32. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis J Am Coll Cardiol 63 2014 299 307
33. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 2550 2583
34. S. Bangalore, B. Toklu, and N. Amoroso Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis BMJ 347 2013 f6625
35. S.-J. Park, D.-W. Park, and Y.-H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
36. A. Pandit, S. Giri, and F.A. Hakim Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials Catheter Cardiovasc Interv 85 2015 34 40
37. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
38. G. Montalescot, S.D. Wiviott, E. Braunwald for the TRITON-TIMI 38 Investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
39. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor vs. clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
40. P.W. Armstrong, Y. Fu, and W.C. Chang Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia Circulation 98 1998 1860 1868
41. M.R. Buchanan Biological basis and clinical implications of acetylsalicylic acid resistance Can J Cardiol 22 2006 149 151
42. P.A. Gurbel The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor Rev Cardiovasc Med 7 Suppl 4 2006 S20 S28
43. M.R. Mueller, A. Salat, and P. Stangl Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty Thromb Haemost 78 1997 1003 1007
44. P.A. Gum, K. Kottke-Marchant, and P.A. Welsh A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
45. J.W. Eikelboom, J. Hirsh, and J.I. Weitz Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
46. J.P. Collet, J. Silvain, O. Barthélémy, and G. Rangé Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Lancet 384 2014 1577 1585
47. G.W. Stone, B. Witzenbichler, and G. Weisz Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623